Atomoxetine, thioridazine, pipophezine in treatment adolescents with ADHD

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


Analysis of published data on the diagnostic criteria used in the qualification of hyperkinetic syndrome found that along with the data on residual-organic failure CNS causes the development of hyperkinetic syndrome expanded range of studies on the endogenous nature of this syndrome. Thus the international “Genomics Consortium psychiatric” (Psychiatric Genomics Consortium) identify common loci in hyperkinetic disorder and schizophrenia which are located on the short arm of the 3rd chromosome (3r21) and on the long arm of chromosome 10 (10q24) and revealed single nucleotide substitutions (SNPs) in the two genes (CACNA1C and CACNB2) which encode proteins that are part of the channels regulating calcium transport into brain cells. Hyperactivity disorder (GR) as a mental disorder (F90) is multifactorial in nature, which requires consideration of clinical symptom in different planes with the release of endogenous and exogenous forms the primary etiological factor for differentiation therapy. Were studied 231 adolescents with a diagnosis of “Attention-Deficit hyperactivity Disorder” (mean age - 17,7 years). The main components of adolescents AHHD are given by BPRS: arousal (3,63 ± 0,06); cognitive (2,94 ± 0,06) and emotional (2,64 ± 0,06) disorder. Patients were split into threatment group: group 1 (n = 23) received Atomoxetine 25mg/day; group 2 (n = 20) received thioridazine 25mg/day, group 3 (n = 22) - pipophezine 50 mg/day. The positive dynamics of disregulatory-motor typeractivity, cognitive and emotional components of ADHD was observed. The aim: to evaluate the influence of Atomoxetine, Thioridazine, Pipophezine on the main psychopatological clinical-components of adolescents AHHD.

Full Text

Restricted Access

About the authors

Vita Valentinovna Glushchenko

Institute of Medical Education, Yaroslav-the-Wise Novgorod State University

Email: vitaglu@mail.ru
MD, PhD, Associate Professor, Head. Department of neurology and psychiatry

References

  1. Глущенко В. В., Шабанов П. Д. Минимальная дисфункция мозга. М.: Бином; 2013.
  2. Ханин Ю. Л. Краткое руководство к применению шкалы реактивной и личностной тревожности Ч. Д. Спилбергера. Л.: 1976.
  3. Sorretti A., Gibiino S., Olgiati P. Pharmacogenetics of antidepressants and mood stabilizer. Handb. Clin. Neuor. 2012; 106: 715-744.
  4. Wender P. H. The hyperactive childe, adolescent, and adult. New York.: Oxford University Press; 1987.

Statistics

Views

Abstract - 443

PDF (Russian) - 270

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2015 Glushchenko V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies